A pragmatic multi-centre randomised controlled trial of fluid loading and level of dependency in high-risk surgical patients undergoing major elective surgery: trial protocol by Cuthbertson, B.H. et al.
 
 
 
 
 
 
 
Cuthbertson, B.H. and Campbell, M.K. and Stott, S.A. and Vale, L. and 
Norrie, J. and Kinsella, J. and Cook, J. and Brittenden, J. and Grant, A. 
(2010) A pragmatic multi-centre randomised controlled trial of fluid 
loading and level of dependency in high-risk surgical patients undergoing 
major elective surgery: trial protocol. Trials, 11 . p. 41. 
 
http://eprints.gla.ac.uk/29902/ 
 
Deposited on: 31 May 2010 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
TRIALS
Cuthbertson et al. Trials 2010, 11:41
http://www.trialsjournal.com/content/11/1/41
Open AccessS T U D Y  P R O T O C O LStudy protocolA pragmatic multi-centre randomised controlled 
trial of fluid loading and level of dependency in 
high-risk surgical patients undergoing major 
elective surgery: trial protocol
Brian H Cuthbertson*1,2, Marion K Campbell2, Stephen A Stott3, Luke Vale2,8, John Norrie4, John Kinsella5, 
Jonathan Cook2, Julie Brittenden6, Adrian Grant7 and FOCCUS Study Group8
Abstract
Background: Patients undergoing major elective or urgent surgery are at high risk of death or significant morbidity. 
Measures to reduce this morbidity and mortality include pre-operative optimisation and use of higher levels of 
dependency care after surgery. We propose a pragmatic multi-centre randomised controlled trial of level of 
dependency and pre-operative fluid therapy in high-risk surgical patients undergoing major elective surgery.
Methods/Design: A multi-centre randomised controlled trial with a 2 * 2 factorial design. The first randomisation is to 
pre-operative fluid therapy or standard regimen and the second randomisation is to routine intensive care versus high 
dependency care during the early post-operative period. We intend to recruit 204 patients undergoing major elective 
and urgent abdominal and thoraco-abdominal surgery who fulfil high-risk surgical criteria. The primary outcome for 
the comparison of level of care is cost-effectiveness at six months and for the comparison of fluid optimisation is the 
number of hospital days after surgery.
Discussion: We believe that the results of this study will be invaluable in determining the future care and clinical 
resource utilisation for this group of patients and thus will have a major impact on clinical practice.
Trial Registration: Trial registration number - ISRCTN32188676
Background
Patients undergoing major elective or urgent surgery are
at high risk of death or significant morbidity. Death
around the time of surgery accounts for nearly one in 20
of all deaths in the UK and the rates are not significantly
declining. Amongst the patients who survive, many suffer
major complications with subsequent impairment of
health and quality of life.
The National Confidential Enquiry into Peri-operative
Deaths shows that such deaths are commonly associated
with cardiac complications [1,2]. Putative contributory
factors include a lack of High Dependency Unit (HDU)
and Intensive Care Unit (ICU) beds, and suboptimal pre-
and post-operative ward care. The Department of
Health's report "Comprehensive Critical Care" [3] pro-
posed that an HDU facility should care for frail patients
who require monitoring or specialised analgesia after sur-
gery without the immediate availability of medical staff,
whereas an ICU-based HDU facility should care for
patients requiring more detailed observation or interven-
tion, including immediate availability of experienced
medical staff. This simple system offers much to be com-
mended as an attempt to allow more cost-effective and
flexible utilisation of critical care services. However, there
has been little research on the effects of ICU care alone
on outcome from major surgery and these guidelines are
based on expert opinion rather than empirical evidence.
Further, they have not been routinely adopted and imple-
mented into current clinical practice; only around 60% of
hospitals have ward-based surgical HDU facilities and
* Correspondence: brian.cuthbertson@sunnybrook.ca
1 Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, 
Toronto, Ontario, Canada
Full list of author information is available at the end of the articleBioMed Central
© 2010 Cuthbertson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Cuthbertson et al. Trials 2010, 11:41
http://www.trialsjournal.com/content/11/1/41
Page 2 of 7fewer hospitals have ICU-based HDU facilities [1,2].
"Comprehensive Critical Care" [4] also identified a need
for a greater evidence-base to justify the huge clinical
resources that are currently invested in critical care ser-
vices throughout the UK. The question remains whether
routine ICU-based postoperative care improves out-
comes after major surgery in a cost-effective manner.
There is also evidence that peri-operative risk can be
reduced by specific interventions applied before surgery.
Pre-operative optimisation and supranormalisation aims
to 'optimise' cardiac index and oxygen delivery through a
pre-operative fluid and inotrope strategy that is main-
tained in the intra-operative and early post-operative
periods [5-7]. Early randomised studies suggested a sig-
nificant outcome advantage from this strategy. Wilson et
al [6] found a mortality of 17% in the control group com-
pared to 3% in the treatment group and claimed that this
represented a cost-effective improvement in peri-opera-
tive care [6]. This study has, however, been criticised
because of the poor outcome in the control group.
Amongst those who consider pre-operative optimisation
and supranormalisation to be effective, there is debate as
to which aspect of the strategy brings about the reduction
in mortality. Furthermore, the practicality of 'full' pre-
operative optimisation and supranormalisation is limited
because ICU-based care is required both before and after
surgery. This has led to consideration of whether compo-
nents that could be applied outside an ICU setting might
still be useful.
This proposal is for a randomised controlled trial to test
two of the most promising (but controversial) aspects of
peri-operative care: firstly, a simple and practical
approach to pre-operative preparation using ward-based
intravenous fluid therapy; and secondly, the routine pro-
vision of intensive care facilities after surgery. We aimed
to test whether ward-based pre-operative fluid loading
and post-operative higher levels of dependency are effec-
tive and cost-effective in high-risk surgical patients
undergoing major elective and urgent surgery.
Methods/Design
A multi-centre, prospective, randomised, controlled trial
with a partial 2 * 2 factorial design conducted in three UK
hospitals, coordinated from the Centre for Healthcare
Randomised Trials (CHaRT) in the Health Services
Research Unit, University of Aberdeen [8,9]. The design
features and estimates used in this protocol were further
informed by the results of a 15-week pilot of the proposed
protocol undertaken in Aberdeen Royal Infirmary, during
which 23 patients were recruited.
Research question
This trial aims to address the question whether: 1) ward-
based pre-operative fluid optimisation and/or 2) routine
post-operative ICU-based care for high risk surgical
patients undergoing major elective and urgent surgery
improves outcome and is cost-effective.
Interventions to be evaluated
Patients will be randomised to a) pre-operative or stan-
dard regimen; and then secondly to b) ICU or HDU for
post-operative care. The partial nature of the factorial
design recognises that some patients may not be able to
be randomised to the ICU or HDU comparison (as ICU
beds cannot always be guaranteed).
Pre-operative fluid therapy or standard regimen
In the pre-operative fluid therapy group patients will be
electively commenced on pre-operative fluid therapy (25
ml/kg) using Hartmann's solution over six hours before
surgery in the ward setting. In the standard fluid regimen
no routine pre-operative fluid therapy will be given. All
patients receiving bowel preparation will be given an
additional 10 ml/kg Hartmann's solution in the 12 hours
before surgery irrespective of trial group allocation (as
this is deemed to be best clinical practice). Patients
receiving "Klean-prep" bowel preparation with 4 litres of
oral fluid will not receive additional IV fluids.
ICU or HDU for post-operative care
The ICU care group will have initial post-operative care
undertaken in the ICU under the care of ICU clinicians
[3]. The HDU care group will have initial post-operative
care undertaken in a surgical HDU under the care of the
surgical team [3].
All non-protocol fluid prescriptions and other manage-
ment decisions (including the movement of the patients
through differing levels of dependency) will be made by
the clinically responsible medical staff.
Inclusion criteria
Inclusion criteria include patients undergoing major elec-
tive and urgent abdominal and thoraco-abdominal sur-
gery who fulfil high-risk surgical criteria [10] who have
signed informed consent. These high risk criteria include
high risk type of surgery, presence of ischaemic heart dis-
ease, history of congestive heart failure, history of cere-
brovascular disease, insulin therapy for diabetes and pre-
operative serum creatinine > 2 mg/dl. Patients who
undergo open, laparoscopic or laparoscopically-assisted
surgery will be eligible.
Exclusion criteria
Exclusion criteria will include New York Heart Associa-
tion grade IV heart failure; clinician concern about safety
of interventions; emergency surgery; chronic renal fail-
ure/creatinine > 300 umol.L-1, lack of informed consent;
age < 16 years; pregnancy; major hepatic surgery,
expected survival < 6 months.
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Participants will be recruited from the elective operating
schedules in the recruiting hospitals and informed con-
sent obtained. Patients will, in general, be identified fol-
lowing a pre-assessment visit at a local hospital or
following their initial appointment with the surgeon.
They will be sent an information leaflet prior to their hos-
pital admission, or given one at their appointment.
Informed consent will be sought from these patients on
their admission to hospital. Participants will be ran-
domised through an interactive voice response (IVR)
automated telephone randomisation service. A minimisa-
tion algorithm will be used, incorporating centre, age, sex
and type of surgery [11]. All participants will be followed
up daily for one week for major morbidity and mortality,
then at hospital discharge and then one, three and six
months after surgery for survival and quality of life.
Outcome measure
a) Pre-operative fluid therapy or standard regimen
The primary outcomes outcome is the number of hospi-
tal days after surgery (length of stay).
b) Routine ICU or HDU for post-operative care [3]
The primary outcome is cost-effectiveness at six months,
measured by the Net Benefit statistic which is calculated
using the following equation: ((λ * QALY) - costs) where λ
indicates society's 'willingness to pay' (λ is typically set at
£20,000 and this value will be used for the main analysis);
QALYs are calculated using EQ-5D scores and costs
include both primary and secondary care costs.
For both comparisons, secondary outcomes include
measures of health status at one month after surgery
measured using SF-36 by patient completed survey
[12,13](with appropriate adjustment to accommodate for
patients who die); changes in health status and quality of
life over 6 months after surgery and quality of life at 48
hours, three and six months after surgery measured using
SF-36 [12,13] and EQ-5D [14]; QALY calculated using
EQ-5D. Other secondary measures include measures of
health care costs including full hospital costs (driven by
critical care utilisation and hospital length of stay) and
primary care costs. Mortality will be measured using
time-to-event analysis and the level of major morbidities
in hospital using Post-Operative Morbidity Survey
(POMS) [15]. The decision to discharge the patient from
hospital was made by the caring team with no involve-
ment of the study personnel. Study outcome measured
during hospital stay were measured by study personnel
not blinded to the intervention. Outcomes measured
after hospital discharge were measured by study person-
nel blinded to the intervention.
Sample size
As the smallest number of patients will be available for
the comparison of ICU and HDU care (as not all patients
will be able to be randomised to this comparison), this
comparison drives the sample size calculation. We aim to
be able to detect 0.45 standard deviations of a difference
in the primary outcome (mean Net Benefit Statistic)
between the two groups. For example, if the standard
deviation of Net Benefits in both groups was about
£10,000, this would equate to being able to detect a differ-
ence in the mean Net Benefit of £4,500. To be able to
detect this level of difference with 80% power and a 5%
level of significance, we will recruit 156 patients to this
comparison. We further estimate that around 10% of
patients will not have data available on all components of
the cost-effectiveness at six months (which include data
which is self-reported) and as such have inflated the
number required to be recruited to this comparison to
174.
In the pilot study we found a 10% failure rate to prog-
ress from the first randomisation (pre-operative fluid) to
the second randomisation (ICU versus HDU) because
ICU care was not available. As such, the total sample size
required to be recruited to the comparison of pre-opera-
tive fluid therapy or standard management needs to be at
least 10% greater than that being sought for the ICU/
HDU comparison. Conservatively, we have assumed that
15% will not be able to be randomised to the ICU/HDU
randomisation and thus estimate that 204 patients be
recruited to the study in total.
We have no reason to expect any loss to follow up for
the primary outcome of the pre-operative fluid compari-
son (as the primary outcome is number of days in hospi-
tal after surgery). Ideally this comparison would have
sufficient power to detect a 0.5 standard deviation change
in number of days in hospital, with 80% power and 5%
significance (requiring data on 128 patients to be avail-
able for analysis). In fact, a total sample size of 204
patients would allow a difference of 0.4 standard devia-
tions of a difference to be detected with at least 80%
power at a 5% level of significance (and over 90% power
to detect a 0.5 standard deviation difference). The trial
patient pathway is presented in figure 1.
The study would also have approximately 90% power to
address the health related quality of life secondary out-
comes. Previous quality of life studies suggest a difference
in means of 0.5 of a standard deviation in Health Related
Quality of Life scores reflects a clinically important
change. The pilot study indicated that such a difference
would translate to around five points in the mean physi-
cal component score of the SF-36 questionnaire.
Trial management
The pilot study suggested that non-compliance with the
proposed protocol will be uncommon. Nevertheless, we
recognise that ICUs must have the ability to discharge
trial patients early according to clinical need; this will be
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formed. Weekly progress meetings will be held in each
clinical centre and at the study Data Centre at CHaRT.
The applicants will form a Trial Management Group,
which will meet monthly. CHaRT will also perform
detailed and regular site reviews and visits to ensure
recruitment. If they are not achieved then they will
undertake further actions to remedy this as required. The
trial will be supervised by a Trial Steering Committee
with an independent Chair. This Committee will oversee
the trial and monitor progress against the milestones. An
independent Data Monitoring Committee (DMC) will,
during the period of recruitment to the trial, be provided
with interim analyses, in strict confidence, together with
any other analyses that the committee may request. The
frequency of any interim analyses will be based on the
judgement of this Committee.
Data analysis
The statistical analyses will be based on all people ran-
domised who are retained in the study until the primary
outcome time points, irrespective of subsequent compli-
ance to treatment allocation. The principal comparisons
will be a) all patients randomised to fluid optimisation
versus all patients not allocated fluid optimisation and b)
all patients randomised to routine ICU care versus all
patients randomised to HDU for post-operative care.
Figure 1 Trial patient pathway.
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Identification of high risk major 
surgical patients n = 300 (100%) 
First randomisation group 
allocation n = 204 (67%) 
Fluid loading n = 102 No fluid loading n = 102 
Operating theatre n = 204 
ICU care n = 87 HDU care n = 87 
Ward care n = 204 
No ICU bed available n = 30 
Hospital discharge n = 204 
6 month follow up n = 156 
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ods for two-group comparisons for continuous, binary
and time-to-event outcomes [9]. All statistical analyses
will be pre-specified in a Statistical Analysis Plan which
will be agreed before any unblinded data is seen. Length
of stay will be analysed using linear regression adjusted
for the minimisation variables [11]. For the net benefit
statistic, linear regression will also be used with adjust-
ment for minimisation variables and the baseline EQ-5D
score. Bootstrapping of the confidence interval for the
mean difference in net-benefit will be performed and sta-
tistical significance determined on the basic of this inter-
val including zero. Further details on the generation of
the components of the net-benefit statistic are given in
the economic analysis section. Health related quality of
life measure will be analysed similarly. Mortality will be
analysed using a Cox-proportional hazards model
adjusted for minimisation factors. POMS will be analysed
using logistic regression adjusted for minimisation cova-
riates. A two-sided 5% significance level will be applied as
evidence of statistical significance for the analyses. Corre-
sponding confidence intervals will be presented.
For the fluid randomisation we plan to include patients
recruited into the pilot study within the analysis as they
have undergone the same interventions and have the
same outcome measures collected (hospital length of
stay). Pilot study data will not be used in the analysis of
ICU length of stay as the primary outcome time point
was changed from 1 year to 6 months as a result of the
pilot.
A single principal analysis is planned six months after
the last person is recruited. If considered appropriate, fol-
low-up of recruits will be extended at this time and a cor-
responding latter analysis will also be conducted once the
latter follow-up data is available. Secondary subgroup
analyses will be investigated through tests for interaction
and will include patients with co-morbidities, cardiac risk
[11], urgency and type of surgery. Stricter levels of statis-
tical significance (2-sided 1% significance level) will be
applied reflecting the exploratory nature of these sub-
group analyses.
Economic analysis
Based on experience gained through the pilot study, costs
to the NHS will be elicited using a "top-down" method.
Resource data will be collected on hospital costs by
patient follow up, case note review and through the
Patient Admissions System. The main drivers of hospital
costs will be critical care utilisation and hospital length of
stay. Primary care resource utilisation, patient costs and
costs to carers will be identified by telephone interview.
NHS resource usage will be costed using appropriate unit
costs. Incremental cost per quality adjusted life year will
be calculated using data elicited from the EQ-5D ques-
tionnaire. For patients who die, a quality of life score of
zero will be applied for measurements after death
[14,16,17]. Uncertainty will be explored using both sto-
chastic (which will utilise the net benefits data) and other
forms of sensitivity analysis [17]. The stochastic analysis
will explore the impact of using different values for soci-
ety's willingness to pay for a QALY (λ) and these data will
be presented in the form of a cost-effectiveness accept-
ability curve. Sensitivity analysis will also be used to
explore the impact of imputing any missing data.
Ethics approval
The Multicentre Research Ethics Committee for Scotland
has approved the study for the UK (Ref 04/MRE10/76).)
The trial has been registered in a public trials registry
(registry number ISRCTN32188676). The trial will be
conducted according to the principles of good practice
provided by Research Governance Guidelines and the
Data Protection Act 1998. The trial is sponsored by the
University of Aberdeen. The Trial Management Group,
through the Trial Steering Committee, will ensure that
adequate systems are in place for monitoring the quality
of the study (compliance with Good Clinical Practice
(GCP)) and appropriate expedited (when appropriate)
and routine reports of adverse effects.
Discussion
It is clear from the existing evidence based that there is a
lack of evidence to guide clinicians and health service
managers on the optimal peri-operative management of
high risk patients. This group of patients has very signifi-
cant morbidity and mortality and strategies need to be
identified to improve these outcomes. We are conducting
this randomised controlled trial to attempt to answer two
important research questions in this patient group which
will supply highly useful evidence on the optimal man-
agement in this group and help guide clinicians as well as
health service managers in their prioritisation and deci-
sion making.
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